interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Levetiracetam

Generic competition · all medicines · read 12 November 2026

Is there a generic of Levetiracetam, and who makes it?

Levetiracetam appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 48 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 3 and 8.9 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Levetiracetam5 dosage-form groups in the Orange Book
48generic makers listed
  1. Levetiracetam appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 48 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 3 and 8.9 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Keppra. 18 generic makers with 68 generic products listed as marketed; the first generic approval is dated 4 November 2008.

199520002005201020152020202520302035018brand 1999Mylan Pharmaceuticals Inc, first approval 4 November 2008Aurobindo Pharma Ltd, first approval 15 January 2009Ingenus Pharmaceuticals Llc, first approval 15 January 2009Lupin Ltd, first approval 15 January 2009Orbion Pharmaceuticals Private Ltd, first approval 15 January 2009Pharmazone, first approval 15 January 2009Torrent Pharmaceuticals Ltd, first approval 15 January 2009Prinston Pharmaceutical Inc, first approval 10 February 2009Novax Pro Pharma Llc, first approval 13 March 2009Oxford Pharmaceuticals Llc, first approval 20 March 2009Zydus Pharmaceuticals Usa Inc, first approval 29 April 2009Rising Pharma Holdings Inc, first approval 28 July 2010Hetero Labs Ltd Unit Iii, first approval 8 October 2010Zhejiang Jingxin Pharmaceutical Co Ltd, first approval 14 December 2010Chartwell Rx Sciences Llc, first approval 14 June 2011Sciegen Pharmaceuticals Inc, first approval 11 June 2021Alkem Laboratories Ltd, first approval 27 May 2022Msn Laboratories Private Ltd, first approval 7 October 2022data datePatent 8802142 listed to expire 7 June 2031Patent 8802142*PED listed to expire 7 December 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Mylan Pharmaceuticals Inc4 November 20083
Aurobindo Pharma Ltd15 January 20094
Ingenus Pharmaceuticals Llc15 January 20094
Lupin Ltd15 January 20094
Orbion Pharmaceuticals Private Ltd15 January 20094
Pharmazone15 January 20094
Torrent Pharmaceuticals Ltd15 January 20094
Prinston Pharmaceutical Inc10 February 20094
Novax Pro Pharma Llc13 March 20094
Oxford Pharmaceuticals Llc20 March 20093
Zydus Pharmaceuticals Usa Inc29 April 20092
Rising Pharma Holdings Inc28 July 20104

6 more makers are listed in the data.

Patents and exclusivities still listed

  • 7 June 2031Patent 8802142 drug product
  • 7 December 2031Patent 8802142*PED

Tablet, Extended Release, Oral

Four or more generic makers listed

Brand listed as marketed: Keppra Xr. 10 generic makers with 20 generic products listed as marketed; the first generic approval is dated 12 September 2011.

200520102015202020252030010brand 2008Actavis Laboratories Fl Inc, first approval 12 September 2011Apotex Inc, first approval 12 September 2011Lupin Limited, first approval 12 September 2011Torrent Pharmaceuticals Ltd, first approval 29 May 2012Prinston Pharmaceutical Inc, first approval 21 May 2015Anda Repository Llc, first approval 23 February 2016Aiping Pharmaceutical Inc, first approval 26 August 2016Hisun Pharmaceutical (Hangzhou) Co Ltd, first approval 28 September 2017Yabao Pharmaceutical Co Ltd Beijing, first approval 11 June 2020Sciegen Pharmaceuticals Inc, first approval 27 November 2020data datePatent 7858122 listed to expire 17 September 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Actavis Laboratories Fl Inc12 September 20112
Apotex Inc12 September 20112
Lupin Limited12 September 20112
Torrent Pharmaceuticals Ltd29 May 20122
Prinston Pharmaceutical Inc21 May 20152
Anda Repository Llc23 February 20162
Aiping Pharmaceutical Inc26 August 20162
Hisun Pharmaceutical (Hangzhou) Co Ltd28 September 20172
Yabao Pharmaceutical Co Ltd Beijing11 June 20202
Sciegen Pharmaceuticals Inc27 November 20202

Patents and exclusivities still listed

  • 17 September 2028Patent 7858122 drug product

Injectable, Intravenous

Four or more generic makers listed

Brand listed as marketed: Keppra and Levetiracetam In Sodium Chloride. 17 generic makers with 39 generic products listed as marketed; the first generic approval is dated 26 May 2010.

200520102015202020252030017brand 2006Xgen Pharmaceuticals Djb Inc, first approval 5 August 2011Hikma Farmaceutica (Portugal) Sa, first approval 13 October 2011Hospira Inc, first approval 6 April 2012Sagent Pharmaceuticals Inc, first approval 26 June 2013Fresenius Kabi Usa Llc, first approval 13 August 2015Eugia Pharma Specialities Ltd, first approval 1 February 2016Mylan Laboratories Ltd, first approval 16 September 2016Gland Pharma Ltd, first approval 25 October 2017Hainan Poly Pharmaceutical Co Ltd, first approval 20 March 2018Micro Labs Ltd, first approval 9 August 2019Nexus Pharmaceuticals Llc, first approval 6 July 2020Prinston Pharmaceutical Inc, first approval 28 March 2022Msn Laboratories Private Ltd, first approval 15 November 2022Baxter Healthcare Corp, first approval 2 October 2023Hikma Pharmaceuticals Usa Inc, first approval 12 February 2024B Braun Medical Inc, first approval 27 February 2024Caplin Steriles Ltd, first approval 16 January 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Xgen Pharmaceuticals Djb Inc5 August 20111
Hikma Farmaceutica (Portugal) Sa13 October 20111
Hospira Inc6 April 20121
Sagent Pharmaceuticals Inc26 June 20131
Fresenius Kabi Usa Llc13 August 20154
Eugia Pharma Specialities Ltd1 February 20164
Mylan Laboratories Ltd16 September 20164
Gland Pharma Ltd25 October 20173
Hainan Poly Pharmaceutical Co Ltd20 March 20181
Micro Labs Ltd9 August 20191
Nexus Pharmaceuticals Llc6 July 20203
Prinston Pharmaceutical Inc28 March 20221

5 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

Four or more generic makers listed

Brand listed as marketed: Keppra. 13 generic makers with 13 generic products listed as marketed; the first generic approval is dated 15 January 2009.

2000200520102015202020252030013brand 2003Actavis Mid Atlantic Llc, first approval 15 January 2009Aurobindo Pharma Ltd, first approval 15 January 2009Bionpharma Inc, first approval 16 January 2009Taro Pharmaceutical Industries Ltd, first approval 10 February 2009Chartwell Molecular Holdings Llc, first approval 3 April 2009Amneal Pharmaceuticals, first approval 27 October 2009Ajenat Pharmaceuticals Llc, first approval 30 September 2010Quagen Pharmaceuticals Llc, first approval 11 April 2012Hetero Labs Ltd Unit Iii, first approval 28 February 2013Alembic Pharmaceuticals Ltd, first approval 9 May 2013Pharmaceutical Associates Inc, first approval 4 June 2015Msn Laboratories Private Ltd, first approval 15 July 2022Adaptis Pharma Private Ltd, first approval 21 November 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Actavis Mid Atlantic Llc15 January 20091
Aurobindo Pharma Ltd15 January 20091
Bionpharma Inc16 January 20091
Taro Pharmaceutical Industries Ltd10 February 20091
Chartwell Molecular Holdings Llc3 April 20091
Amneal Pharmaceuticals27 October 20091
Ajenat Pharmaceuticals Llc30 September 20101
Quagen Pharmaceuticals Llc11 April 20121
Hetero Labs Ltd Unit Iii28 February 20131
Alembic Pharmaceuticals Ltd9 May 20131
Pharmaceutical Associates Inc4 June 20151
Msn Laboratories Private Ltd15 July 20221

1 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, For Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Spritam. No generic is listed as marketed.

2015202020252030203501brand 2015data datePatent 9339489 listed to expire 14 March 2034Patent 9669009 listed to expire 14 March 2034Patent 11160786 listed to expire 14 March 2034
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 March 2034Patent 9339489 drug product
  • 14 March 2034Patent 9669009
  • 14 March 2034Patent 11160786 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.